Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma

Oncogene

Volumn 33, Issue 24, 2014, Pages 3151-3160

  Guo, Y ^a   Chirieac, L R ^b   Bueno, R ^a   Pass, H ^c   Wu, W ^a   Malinowska, I A ^a   Kwiatkowski, D J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

mesothelioma; mTOR; rapamycin; TSC1; TSC2

Indexed keywords

CRE RECOMBINASE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; ONCOPROTEIN; PROTEIN P53; RAPAMYCIN; TSC1 PROTEIN; TUBERIN; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER TISSUE; CARCINOGENESIS; CONTROLLED STUDY; DRUG TARGETING; EMBRYO; GENE EXPRESSION; GENE FREQUENCY; GENE LOSS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT ASCITES; MESOTHELIOMA CELL LINE; MOUSE; MOUSE MODEL; NONHUMAN; PERITONEUM MESOTHELIOMA; PRIORITY JOURNAL; SURVIVAL RATE; TISSUE MICROARRAY; TRANSACTIVATION; TUMOR MODEL; TUMOR VOLUME;

ADENOVIRIDAE; MAMMALIA; MUS;

ANIMALS; BLOTTING, WESTERN; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MESOTHELIOMA; MICE; MICE, KNOCKOUT; PERITONEAL NEOPLASMS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84902437561     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.280     Document Type: Article

References (35)

1. Ettinger DS, Akerley W, Borghaei H, Chang A, Cheney RT, Chirieac LR et al. Malignant pleural mesothelioma. J Natl Compr Canc Netw 2012; 10: 26-41.
2. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol 2009; 27: 2081-2090.
3. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644.
4. Kwiatkowski DJ, Thiele E, Whittemore VH. Tuberous sclerosis complex. Wiley-VCH: Weinheim, Germany, 2010 3-7.
5. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011; 331: 1199-1203.
6. Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P, Knowles MA. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res 2009; 15: 6008-6017.
7. Qin W, Bajaj V, Malinowska I, Lu X, MacConaill L, Wu CL et al. Angiomyolipoma have common mutations in TSC2 but no other common genetic events. PLoS One 2011; 6: e24919.
8. Wagner AJ, Malinowska-Kolodziej I, Morgan JA, Qin W, Fletcher CD, Vena N et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol 2010; 28: 835-840.
9. Hammerman PS, Hayes DN, Wilkerson MD, Schultz N, Bose R, Chu A et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519-525.
10. Dickson MA, Schwartz GK, Antonescu CR, Kwiatkowski DJ, Malinowska IA. Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates. Int J Cancer 2012; 132: 1711-1717.
11. Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012; 338: 221.
12. Menges CW, Sementino E, Talarchek J, Xu J, Chernoff J, Peterson JR et al. Group I p21-activated kinases (PAKs) promote tumor cell proliferation and survival through the AKT1 and Raf-MAPK pathways. Mol Cancer Res 2012; 10: 1178-1188.
13. Altomare DA, You H, Xiao GH, Ramos-Nino ME, Skele KL, De Rienzo A et al. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 2005; 24: 6080-6089.
14. Goto J, Talos DM, Klein P, Qin W, Chekaluk YI, Anderl S et al. Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex. Proc Natl Acad Sci USA 2011; 108: E1070-E1079.
15. Auricchio N, Malinowska I, Shaw R, Manning BD, Kwiatkowski DJ. Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC). PLoS One 2012; 7: e31900.
16. Liang MC, Ma J, Chen L, Kozlowski P, Qin W, Li D et al. TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity. Oncogene 2010; 29: 1588-1597.
17. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009; 284: 8023-8032.
18. Menon S, Manning BD. Common corruption of the mTOR signaling network in human tumors. Oncogene 2008; 27(Suppl 2): S43-S51.
19. Bianchi AB, Mitsunaga SI, Cheng JQ, Klein WM, Jhanwar SC, Seizinger B et al. High frequency of inactivating mutations in the neurofibromatosis typ. 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 1995; 92: 10854-10858.
20. Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF et al. Neurofibromatosis typ. 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 1995; 55: 1227-1231.
21. Suzuki Y, Murakami H, Kawaguchi K, Tanigushi T, Fujii M, Shinjo K et al. Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol Med Report 2009; 2: 181-188.
22. Hoda MA, Mohamed A, Ghanim B, Filipits M, Hegedus B, Tamura M et al. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy. J Thorac Oncol 2011; 6: 852-863.
23. Opitz I, Soltermann A, Abaecherli M, Hinterberger M, Probst-Hensch N, Stahel R et al. PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg 2008; 33: 502-506.
24. Brevet M, Shimizu S, Bott MJ, Shukla N, Zhou Q, Olshen AB et al. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy. J Thorac Oncol 2011; 6: 864-874.
25. Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V et al. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 2006; 66: 352-361.
26. Wilson SM, Barbone D, Yang TM, Jablons DM, Bueno R, Sugarbaker DJ et al. mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids. Am J Respir Cell Mol Biol 2008; 39: 576-583.
27. Meikle L, Pollizzi K, Egnor A, Kramvis I, Lane H, Sahin M et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci 2008; 28: 5422-5432.
28. Reddel RR, Malan-Shibley L, Gerwin BI, Metcalf RA, Harris CC. Tumorigenicity of human mesothelial cell line transfected with EJ-ras oncogene. J Natl Cancer Inst 1989; 81: 945-948.
29. Lopez-Lago MA, Okada T, Murillo MM, Socci N, Giancotti FG. Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol 2009; 29: 4235-4249.
30. James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer-Rachamimov AO et al. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol 2009; 29: 4250-4261.
31. Kwiatkowski DJ, Zhang H, Bandura JL, Heiberger KM, Glogauer M, el-Hashemite N et al. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet 2002; 11: 525-534.
32. Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev 2000; 14: 994-1004.
33. Seager C, Puzio-Kuter AM, Cordon-Cardo C, McKiernan J, Abate-Shen C. Mouse models of human bladder cancer as a tool for drug discovery. Curr Protoc Pharmacol 2010, Chapter 14: Unit14 14.
34. Penno MB, Askin FB, Ma H, Carbone M, Vargas MP, Pass HI. High CD44 expression on human mesotheliomas mediates association with hyaluronan. Cancer J Sci Am 1995; 1: 196-203.
35. Burt BM, Rodig SJ, Tilleman TR, Elbardissi AW, Bueno R, Sugarbaker DJ. Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. Cancer 2011; 117: 5234-5244.